What is Elicio Therapeutics, Inc.'s earnings per share (EPS)?

Elicio Therapeutics, Inc. (ELTX) reported diluted earnings per share of -$2.58 for fiscal year 2025. This represents a 39.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Elicio Therapeutics, Inc. (ELTX) Financials

ELTX

FY2025 annual

Net Income -$39.6M +23.8% YoY

EPS (Diluted) -$2.58 +39.3% YoY

Free Cash Flow -$37.0M +0.5% YoY

Operating Cash Flow -$37.0M +0.3% YoY

Market Cap $50.5M as of Oct 5, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 6.4x on $7.9M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ELTX SEC filings page.

This page shows Elicio Therapeutics, Inc. (ELTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ELTX FY2025 2026-10-03

Elicio remains a development-stage business whose operating losses are funded externally, while minimal capital spending keeps cash use tied to research.

Cash conversion closely mirrors reported losses: in FY2025, operating cash flow was -$37.0M against a net loss of $39.6M, while free cash flow was nearly identical because capital expenditures were only $16K. That combination indicates the cash requirement is overwhelmingly ongoing research and operating expense, rather than heavy investment in physical assets.

External financing is the operating model, not a supplement: financing inflows of $36.7M in FY2025 effectively offset the year's operating cash use. The balance sheet improved from negative equity in FY2024 to positive equity of $1.6M, but debt-to-equity reached 5.8x, leaving little equity cushion relative to liabilities.

Research spending drives the cost structure: FY2025 research and development was $24.9M versus an operating loss of $37.7M, while selling, general and administrative expense was $12.8M. The current ratio of 2.4x and reported liquidity of six months provide short-term balance-sheet context, but do not change the business's reliance on continuing financing.

Financial Health Signals

Financial health score not available

Elicio Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

4/7

Elicio Therapeutics, Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Elicio Therapeutics, Inc. reported a net loss of $39.6M while operations used $37.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Elicio Therapeutics, Inc. reported an operating loss of $37.7M against $1.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$10.3M

YoY-3.4%

QoQ+2.2%

Elicio Therapeutics, Inc.'s EBITDA was -$10.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 3.4% from the same quarter a year earlier. Against the prior quarter it is up 2.2%.

Net Income

-$8.2M

YoY+22.2%

QoQ+30.5%

Elicio Therapeutics, Inc. reported -$8.2M in net income in Q2 2026. This represents an increase of 22.2% from the same quarter a year earlier. Against the prior quarter it is up 30.5%.

EPS (Diluted)

-$0.43

YoY+34.8%

QoQ+33.8%

Elicio Therapeutics, Inc. earned -$0.43 per diluted share (EPS) in Q2 2026. This represents an increase of 34.8% from the same quarter a year earlier. Against the prior quarter it is up 33.8%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$23.5M

YoY+6.3%

QoQ+57.1%

5Y CAGR-27.5%

Elicio Therapeutics, Inc. held $23.5M in cash against $9.5M in long-term debt as of Q2 2026.

Shares Outstanding

26M

YoY+60.9%

QoQ+40.5%

5Y CAGR-2.5%

Elicio Therapeutics, Inc. had 26M shares outstanding in Q2 2026. This represents an increase of 60.9% from the same quarter a year earlier. Against the prior quarter it is up 40.5%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-103.5%

YoY+472.3pp

Elicio Therapeutics, Inc.'s ROE was -103.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 472.3 percentage points from the same quarter a year earlier.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$6.8M

YoY-2.8%

QoQ+0.8%

Elicio Therapeutics, Inc. invested $6.8M in research and development in Q2 2026. This represents a decrease of 2.8% from the same quarter a year earlier. Against the prior quarter it is up 0.8%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

ELTX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ELTX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Revenue	N/A	N/A	N/A	N/A	$2.3M-91.9%	$28.3M+883.1%	$2.9M
Cost of Revenue	N/A	N/A	N/A	N/A	$0-100.0%	$433K-63.6%	$1.2M
Gross Profit	N/A	N/A	N/A	N/A	$2.3M-91.7%	$27.9M+1549.6%	$1.7M
R&D Expenses	N/A	$24.9M-26.0%	$33.7M+41.1%	$23.8M+31.7%	$18.1M-62.8%	$48.7M+24.9%	$39.0M
SG&A Expenses	N/A	$12.8M+13.1%	$11.3M-4.8%	$11.9M+111.3%	$5.6M-69.5%	$18.5M+2.8%	$18.0M
Operating Income	N/A	-$37.7M+16.2%	-$45.0M-25.9%	-$35.7M-50.6%	-$23.7M+39.6%	-$39.3M+28.9%	-$55.3M
EBITDA	N/A	-$37.5M+16.0%	-$44.7M-26.3%	-$35.4M-51.5%	-$23.3M+40.5%	-$39.2M+28.9%	-$55.2M
Interest Expense	N/A	$1.1M+149.0%	$455K-57.0%	$1.1M-70.6%	$3.6M+294.7%	-$1.8M+79.1%	-$8.8M
Income Tax	N/A	$0	$0	$0	$0	$0	$0
Net Income	N/A	-$39.6M+23.8%	-$51.9M-47.5%	-$35.2M-24.8%	-$28.2M+48.3%	-$54.6M+31.9%	-$80.1M
EPS (Basic)	N/A	-$2.58+39.3%	-$4.25+38.9%	-$6.96+92.2%	-$89.27-4525.4%	-$1.93+64.5%	-$5.43
EPS (Diluted)	—	-$2.58+39.3%	-$4.25	-$6.96	-$89.27	-$1.93	-$5.43
Diluted Shares (Avg)	N/A	15M+25.5%	12M	5M	315,998	28M	15M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$6.8M-2.8%	$6.8M-13.1%	N/A	$5.0M-30.1%	$7.0M-14.4%	$7.8M+2.9%	N/A	$7.2M-0.8%
SG&A Expenses	$3.6M+17.3%	$3.8M+30.0%	N/A	$3.0M-4.1%	$3.1M+12.4%	$3.0M+10.3%	N/A	$3.1M-10.6%
Operating Income	-$10.4M-3.3%	-$10.6M+1.2%	N/A	-$8.0M+22.2%	-$10.1M+7.6%	-$10.7M-4.8%	N/A	-$10.3M+4.0%
EBITDA	-$10.3M-3.4%	-$10.6M+1.2%	N/A	-$7.9M+23.2%	-$10.0M+7.7%	-$10.7M-5.2%	N/A	-$10.3M+4.0%
Interest Expense	$410K+111.3%	$407K+131.3%	N/A	$426K+210.9%	$194K+295.9%	$176K+388.9%	N/A	$137K+13600.0%
Income Tax	$0	$0	N/A	$0	$0	$0	N/A	$0
Net Income	-$8.2M+22.2%	-$11.8M-5.5%	N/A	-$10.1M+46.5%	-$10.6M-46.1%	-$11.2M+5.2%	N/A	-$18.8M-76.7%
EPS (Basic)	-$0.43+34.8%	-$0.65+25.3%	-$0.49+52.0%	-$0.60+56.8%	-$0.66-3.1%	-$0.87+24.3%	-$1.02+72.9%	-$1.39-9.4%
EPS (Diluted)	-$0.43+34.8%	-$0.65+25.3%	-$0.49+52.0%	-$0.60+56.8%	-$0.66-3.1%	-$0.87+24.3%	-$1.02+72.9%	-$1.39
Diluted Shares (Avg)	19M+19.8%	18M+40.6%	N/A	17M+22.9%	16M+42.3%	13M+26.1%	N/A	14M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.

ELTX Balance Sheet

ELTX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Total Assets	$25.9M-8.2%	$28.2M+3.8%	$27.1M+19.8%	$22.7M-76.5%	$96.5M+103.8%	$47.3M
Current Assets	$19.3M-6.7%	$20.7M+26.6%	$16.3M+52.5%	$10.7M-88.3%	$91.2M+115.7%	$42.3M
Cash & Equivalents	$18.6M+5.4%	$17.6M+36.6%	$12.9M+109.5%	$6.2M-93.1%	$88.8M+156.5%	$34.6M
Short-Term Investments	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0
Total Liabilities	$24.2M-38.7%	$39.5M+150.4%	$15.8M-87.4%	$124.8M-27.0%	$171.0M+24.1%	$137.8M
Current Liabilities	$8.1M-29.6%	$11.5M+18.1%	$9.8M+42.0%	$6.9M-39.2%	$11.3M-89.5%	$107.4M
Non-Current Liabilities	$16.1M-42.4%	$28.0M+364.7%	$6.0M-94.9%	$117.9M-26.2%	$159.8M+426.4%	$30.3M
Long-Term Debt	$9.4M-53.0%	$20.0M	N/A	N/A	$0-100.0%	$635K
Total Equity	$1.6M+114.5%	-$11.3M-199.5%	$11.4M+111.1%	-$102.1M-37.0%	-$74.5M+17.6%	-$90.4M
Retained Earnings	-$233.7M-20.4%	-$194.1M-36.5%	-$142.2M-32.9%	-$107.0M+50.3%	-$215.1M-34.0%	-$160.6M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$31.3M+6.1%	$22.7M-19.4%	$25.9M-8.2%	$28.3M-26.3%	$29.5M+87.5%	$28.1M+15.0%	$28.2M+3.8%	$38.4M+23.9%
Current Assets	$25.5M+12.8%	$16.2M-22.6%	$19.3M-6.7%	$21.5M-30.0%	$22.6M+237.8%	$20.9M+48.2%	$20.7M+26.6%	$30.6M+53.8%
Cash & Equivalents	$23.5M+6.3%	$14.9M-18.5%	$18.6M+5.4%	$20.6M-20.8%	$22.1M+544.9%	$18.4M+54.8%	$17.6M+36.6%	$26.0M+75.3%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$23.4M-15.5%	$24.1M+25.4%	$24.2M-38.7%	$24.5M-57.4%	$27.7M+59.1%	$19.2M-1.9%	$39.5M+150.4%	$57.4M+224.1%
Current Liabilities	$9.2M-7.3%	$7.2M-36.7%	$8.1M-29.6%	$6.5M-27.8%	$9.9M+30.8%	$11.4M+91.8%	$11.5M+18.1%	$9.0M-21.5%
Non-Current Liabilities	$14.2M-20.1%	$16.9M+115.9%	$16.1M-42.4%	$18.0M-62.9%	$17.8M+81.0%	$7.8M-42.7%	$28.0M+364.7%	$48.4M+678.0%
Long-Term Debt	$9.5M+2.1%	$9.5M	$9.4M-53.0%	$9.7M	$9.3M	N/A	$20.0M	N/A
Total Equity	$7.9M+332.8%	-$1.4M-116.1%	$1.6M+114.5%	$3.8M+120.1%	$1.8M+211.0%	$8.9M+82.8%	-$11.3M-199.5%	-$19.0M-242.9%
Retained Earnings	-$253.7M-17.5%	-$245.5M-19.6%	-$233.7M-20.4%	-$226.0M-25.5%	-$215.9M-33.9%	-$205.3M-33.3%	-$194.1M-36.5%	-$180.1M-35.2%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

ELTX Cash Flow Statement

ELTX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Cash Flow	-$37.7M	-$37.0M+0.3%	-$37.1M-13.4%	-$32.7M-47.4%	-$22.2M+57.9%	-$52.6M-130.0%	-$22.9M
Depreciation & Amortization	N/A	$204K-36.4%	$321K-16.0%	$382K-2.1%	$390K+328.6%	$91K-7.1%	$98K
Stock-Based Compensation	N/A	$2.7M+85.7%	$1.5M+23.2%	$1.2M+103.6%	$579K-95.2%	$12.0M+155.3%	$4.7M
Capital Expenditures	N/A	$16K-81.6%	$87K+31.8%	$66K-89.9%	$654K+71.2%	$382K+831.7%	$41K
Free Cash Flow	N/A	-$37.0M+0.5%	-$37.2M-13.4%	-$32.8M-43.5%	-$22.8M+56.9%	-$53.0M-131.3%	-$22.9M
Investing Cash Flow	N/A	-$16K+81.0%	-$84K-162.5%	-$32K+95.1%	-$654K-71.2%	-$382K-831.7%	-$41K
Financing Cash Flow	$39.0M	$36.7M-13.3%	$42.3M+9.6%	$38.6M+82.1%	$21.2M-80.2%	$107.2M+104.5%	$52.4M
Share Buybacks	N/A	N/A	$0-100.0%	$150K	$0	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$8.2M+8.8%	-$11.6M-15.1%	-$6.8M+22.3%	-$11.1M-52.4%	-$8.9M-0.2%	-$10.1M+16.5%	-$8.7M+11.6%	-$7.3M-40.3%
Depreciation & Amortization	$100K0.0%	$46K-13.2%	$49K-42.4%	$100K	$100K0.0%	$53K-35.4%	$85K+6.3%	$0
Stock-Based Compensation	$935K+31.7%	$868K+67.9%	N/A	$698K+122.3%	$710K+102.9%	$517K+59.6%	N/A	$314K-7.4%
Capital Expenditures	N/A	N/A	$16K-64.4%	$0	N/A	N/A	$45K	$0-100.0%
Free Cash Flow	N/A	N/A	-$6.8M+22.5%	-$11.1M-52.4%	N/A	N/A	-$8.8M+11.2%	-$7.3M-39.1%
Investing Cash Flow	N/A	N/A	-$16K+64.4%	$0	$0+100.0%	$0-100.0%	-$45K	$0+100.0%
Financing Cash Flow	$16.5M+38.4%	$8.0M-22.3%	$4.9M+2042.3%	$9.6M-68.9%	$11.9M+3675.9%	$10.3M-6.3%	$227K-96.8%	$30.8M+51156.7%
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0

Not reported in any period shown, so not listed: Dividends Paid.

ELTX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ELTX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Gross Margin	N/A	N/A	N/A	100.0%+1.5pp	98.5%+39.8pp	58.7%
Operating Margin	N/A	N/A	N/A	-1031.4%	-138.8%	-1919.2%
Net Margin	N/A	N/A	N/A	-1225.9%	-192.8%	-2781.5%
Return on Equity	-2418.8%	N/A	-309.5%	N/A	N/A	N/A
Return on Assets	-153.0%+31.2pp	-184.2%-54.5pp	-129.7%-5.2pp	-124.5%-67.9pp	-56.5%+112.7pp	-169.2%
Current Ratio	2.38+0.6x	1.80+0.1x	1.68+0.1x	1.56-6.5x	8.08+7.7x	0.39
Debt-to-Equity	5.75	N/A	1.39	N/A	N/A	N/A
Asset Turnover	N/A	N/A	N/A	0.10-0.2x	0.29+0.2x	0.06
FCF Margin	N/A	N/A	N/A	-992.3%	-187.3%	-796.1%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-103.5%+472.3pp	N/A	N/A	-264.2%	-575.9%	-125.9%+117.0pp	N/A	N/A
Return on Assets	-26.2%+9.5pp	-52.1%-12.3pp	N/A	-35.6%+13.4pp	-35.8%+10.1pp	-39.8%+8.5pp	N/A	-49.1%-14.7pp
Current Ratio	2.77+0.5x	2.24+0.4x	2.38+0.6x	3.29-0.1x	2.28+1.4x	1.83-0.5x	1.80+0.1x	3.40+1.7x
Debt-to-Equity	1.20-3.9x	N/A	5.75	2.55	5.09	2.16-1.9x	N/A	N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Elicio Therapeutics, Inc. ELTX	FY2025	N/A	-$39.6M	N/A	$50.5M	—
NeOnc Technologies Holdings, Inc. NTHI	FY2025	$40K	N/A	N/A	$86.1M	—
SELLAS Life Sciences Group, Inc. SLS	FY2025	N/A	-$26.9M	N/A	$2.4B	—
C4 Therapeutics, Inc. CCCC	FY2025	$35.9M	-$105.0M	N/A	$362.9M	65/100
Innate Pharma S.A. IPHA	FY2025	$50.0M	N/A	N/A	$174.3M	—
Kyverna Therapeutics, Inc. KYTX	FY2025	N/A	-$161.3M	N/A	$384.7M	—

Where Elicio Therapeutics, Inc. Ranks

Frequently Asked Questions

Is Elicio Therapeutics, Inc. profitable?

No, Elicio Therapeutics, Inc. (ELTX) reported a net income of -$39.6M in fiscal year 2025.

What is Elicio Therapeutics, Inc.'s EBITDA?

Elicio Therapeutics, Inc. (ELTX) had EBITDA of -$37.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Elicio Therapeutics, Inc. have?

As of fiscal year 2025, Elicio Therapeutics, Inc. (ELTX) had $18.6M in cash and equivalents against $9.4M in long-term debt.

What is Elicio Therapeutics, Inc.'s return on equity (ROE)?

Elicio Therapeutics, Inc. (ELTX) has a return on equity of -2418.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Elicio Therapeutics, Inc.'s free cash flow?

Elicio Therapeutics, Inc. (ELTX) recorded an outflow of $37.0M in free cash flow during fiscal year 2025. This represents a 0.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Elicio Therapeutics, Inc.'s operating cash flow?

Elicio Therapeutics, Inc. (ELTX) recorded an outflow of $37.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Elicio Therapeutics, Inc.'s total assets?

Elicio Therapeutics, Inc. (ELTX) had $25.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Elicio Therapeutics, Inc.'s capital expenditures?

Elicio Therapeutics, Inc. (ELTX) invested $16K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Elicio Therapeutics, Inc. spend on research and development?

Elicio Therapeutics, Inc. (ELTX) invested $24.9M in research and development during fiscal year 2025.

How many shares does Elicio Therapeutics, Inc. have outstanding?

Elicio Therapeutics, Inc. (ELTX) had 18M shares outstanding as of fiscal year 2025.

What is Elicio Therapeutics, Inc.'s current ratio?

Elicio Therapeutics, Inc. (ELTX) had a current ratio of 2.38 as of fiscal year 2025, which is generally considered healthy.

What is Elicio Therapeutics, Inc.'s debt-to-equity ratio?

Elicio Therapeutics, Inc. (ELTX) had a debt-to-equity ratio of 5.75 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Elicio Therapeutics, Inc.'s return on assets (ROA)?

Elicio Therapeutics, Inc. (ELTX) had a return on assets of -153.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Elicio Therapeutics, Inc.'s P/E ratio?

Elicio Therapeutics, Inc. (ELTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $50.5M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Elicio Therapeutics, Inc.'s price-to-sales ratio?

Elicio Therapeutics, Inc. (ELTX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $50.5M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Elicio Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Elicio Therapeutics, Inc. (ELTX) held $18.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $37.0M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Elicio Therapeutics, Inc.'s Piotroski F-Score?

Elicio Therapeutics, Inc. (ELTX) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Elicio Therapeutics, Inc.'s earnings high quality?

Elicio Therapeutics, Inc. (ELTX) reported a net loss of $39.6M while operations used $37.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Elicio Therapeutics, Inc. cover its interest payments?

Elicio Therapeutics, Inc. (ELTX) reported an operating loss of $37.7M against $1.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.